Cooley M&A

JANUARY 22, 2025

Public company deals: Smaller bites in more focused therapeutic areas The landscape for public company sales in the life sciences sector in 2024 was notably quieter than expected, with anticipated high-profile deals failing to materialize. Similarly, Novo Holdings $16.5

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

OfficeHours

JULY 18, 2023

In this industry, owning 50 to 100 or more veterinary centers gives you procurement advantages in that you can buy much higher volumes of suppliers (syringes, medical equipment, etc.) investment banking, private equity , VC, etc.) and thus receive volume discounts with better pricing. and how our process works.

Private Equity 130

Private Equity Equities Investment Mergers and Acquisitions 130

Cooley M&A

OCTOBER 19, 2022

Atlas Receives Strategic Investment From Sixth Street Growth. Sixth Street Invests in Blueprint Medicines. Notable public deals. Amazon to Acquire One Medical for $3.9 Amazon to Acquire One Medical for $3.9 Lavoro to Become Publicly Traded Through Business Combination With TPB Acquisition Corporation I.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

Focus Investment Banking

JUNE 13, 2023

according to a recent report by researchers from the Harvard Medical School and the Harvard Business School that was published in JAMA Internal Medicine. Formerly owned by Tahoe Investment Group, which bought the company in April 2017, Alliance was acquired by Akumin, a publicly traded company, in June 2021 for $820 million.

Hospitality 52

Hospitality Private Equity Medical Mergers and Acquisitions 52

Cooley M&A

JANUARY 22, 2020

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 Year of the Life Sciences Mega-Deals. billion acquisition of The Medicines Company.

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 25, 2023

Some sponsors, while unable to present compelling take-private proposals to targets, have deployed capital in private investments in public equity (PIPEs) of public targets, marketing these investments as both a vote of confidence for the incumbent board and much-needed liquidity to help the target weather the downturn.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52